2023 - Research.com Medicine in Australia Leader Award
2023 - Research.com Microbiology in Australia Leader Award
2022 - Research.com Microbiology in Australia Leader Award
2015 - Fellow of the Australian Academy of Health and Medical Science
2014 - Fellow of the Royal Society of New Zealand
David L. Paterson mainly investigates Microbiology, Intensive care medicine, Antibiotics, Antibiotic resistance and Antibacterial agent. David L. Paterson interconnects Klebsiella pneumoniae, Enterobacteriaceae, Escherichia coli and Molecular epidemiology in the investigation of issues within Microbiology. His Intensive care medicine study incorporates themes from Observational study, Health care and Colistin.
His Antibiotics research is multidisciplinary, relying on both Prospective cohort study and Pharmacodynamics. His Antibiotic resistance research is multidisciplinary, incorporating elements of Antimicrobial, Drug resistance, Acinetobacter baumannii and Environmental health. His Antibacterial agent study combines topics in areas such as Cefepime, New Delhi metallo-beta-lactamase 1, Acinetobacter, Tigecycline and Internal medicine.
David L. Paterson mostly deals with Microbiology, Antibiotics, Internal medicine, Intensive care medicine and Antibiotic resistance. David L. Paterson studies Microbiology, focusing on Drug resistance in particular. His biological study spans a wide range of topics, including Pharmacodynamics and Dosing.
His research in Internal medicine intersects with topics in Bacteremia, Surgery, Gastroenterology and Carbapenem. His studies deal with areas such as Colistin and Pneumonia as well as Intensive care medicine. His Antibiotic resistance study incorporates themes from Multiple drug resistance, Antimicrobial and Acinetobacter baumannii.
His scientific interests lie mostly in Antibiotics, Internal medicine, Microbiology, Antibiotic resistance and Clinical trial. His research investigates the connection between Antibiotics and topics such as Escherichia coli that intersect with problems in Drug resistance. Internal medicine is closely attributed to Bacteremia in his research.
His study in Microbiology is interdisciplinary in nature, drawing from both Pseudomonas aeruginosa and Klebsiella pneumoniae. In his study, which falls under the umbrella issue of Antibiotic resistance, Illumina dye sequencing and Intensive care unit is strongly linked to Metagenomics. The Clinical trial study combines topics in areas such as Intensive care, Intensive care medicine, Lopinavir and Ritonavir.
His main research concerns Internal medicine, Clinical trial, Microbiology, Colistin and Antibiotics. His Internal medicine research is multidisciplinary, incorporating perspectives in Bacteremia, Piperacillin/tazobactam, Piperacillin and Ceftriaxone. His study in Antibiotic resistance and Multiple drug resistance are all subfields of Microbiology.
His Antibiotic resistance research is multidisciplinary, incorporating elements of Antimicrobial and Phylogenetic tree. The study incorporates disciplines such as Klebsiella pneumoniae, MCR-1 and Intensive care medicine in addition to Colistin. His research integrates issues of Adverse effect, Enterobacteriaceae and Bacteria in his study of Antibiotics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A-P Magiorakos;A Srinivasan;R B Carey;Y Carmeli.
Clinical Microbiology and Infection (2012)
Extended-spectrum beta-lactamases: a clinical update.
David L. Paterson;Robert A. Bonomo.
Clinical Microbiology Reviews (2005)
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
David L. Paterson;Susan Swindells;Jeffrey Mohr;Michelle Brester.
Annals of Internal Medicine (2000)
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
Timothy H. Dellit;Robert C. Owens;John E. McGowan;Dale N. Gerding.
Clinical Infectious Diseases (2007)
Acinetobacter baumannii: Emergence of a Successful Pathogen
Anton Yariv Peleg;Harald Seifert;David L Paterson;David L Paterson.
Clinical Microbiology Reviews (2008)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy;Mark Alexander Howard Toleman;Timothy Rutland Walsh;Jay Bagaria.
Lancet Infectious Diseases (2010)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Evelina Tacconelli;Elena Carrara;Alessia Savoldi;Stephan Harbarth.
Lancet Infectious Diseases (2017)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L Silvia Munoz-Price;L Silvia Munoz-Price;Laurent Poirel;Robert A Bonomo;Robert A Bonomo;Mitchell J Schwaber.
Lancet Infectious Diseases (2013)
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Jian Li;Roger Leigh Nation;John D Turnidge;Robert W Milne.
Lancet Infectious Diseases (2006)
Resistance in Gram-Negative Bacteria: Enterobacteriaceae
David L. Paterson.
The American Journal of Medicine (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: